We are engaged in developing microbially-expressed proteins & peptides for therapeutic use. We have a robust pipeline of biosimilar/biologic products under development under various stages of laboratory development, pre-clinical & clinical testing.
One of our products launched by us in the market is a life-saving medication – recombinant Streptokinase injection (brand: Streptolev®), a thrombolytic drug used for treating acute myocardial infarction (AMI) commonly known as “heart attack”. Levim is one of the leading producers of streptokinase injection in the world.
Other products that we are working on are for unmet needs in therapeutic areas of Type-2 diabetes, oncology, haematology, inflammation & other metabolic disorders.
On the innovation front, we are currently involved in developing proprietary drug delivery technologies for small and large molecules (<20KDa), that would serve as a platform technology for overcoming the limitations of current liposomal and polymer-encapsulation technologies such as inefficient bioavailability, early degradation/short half-life, uncontrolled release patterns, burst-release phenomena and non-targeted delivery.